Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Net Sales in the U.S.: $824M in FY2025, up 89.0% from a year earlier.
Latest, FY2025
824
Period ended Dec 31, 2025
Change on a year earlier
+89.0%
436 in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Where the FY2025 figure comes from
“|| Scemblix | Oncology | Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP); Ph+ CML in CP with the T315I mutation | 824 | 89 | 461 | 82 | 78 | 1 285 | 87 | 85”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net Sales in the U.S. ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 824 | +89.0% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 436 | – | Novartis Form 6-K (0001370368-25-000007) ↗ |
Breakdown
What makes up net Sales in the U.S.
Cite this data
StockData. (2026). Novartis Net Sales in the U.S. ($M), annual FY2024–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-scemblix-us-sales
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.